MK-1045 in combination with rituximab as first-line treatment for follicular lymphoma (currently only in phase II trial). (chinadrugtrials.org.cn) - Oct 7, 2026 - P2/3 | N=114 | Sponsor: Merck R&D (China) Co., Ltd.
New P2/3 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20
|